Science Corporation, the Alameda, California-based medical device company building retinal implants, said on November 17, 2026, that it closed a $400 million Series D round. Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech took part; the company did not name a lead investor. A new valuation was not disclosed, but the round pushes Science's total funding since its 2021 founding past $900 million, following a $230 million Series C closed in March 2026.
What is Prima, and who is it for?
Prima is a wireless, subretinal photovoltaic implant roughly 2mm by 2mm, paired with a pair of glasses. The glasses project near-infrared light that the implant converts into electrical stimulation, acting as an artificial photoreceptor layer for patients who have lost central vision to geographic atrophy, an advanced form of age-related macular degeneration and a leading cause of blindness in older adults.
The device received a CE mark in July 2026 and is now commercially available across 30 European countries. In the 36-month PRIMAvera trial, patients saw a mean improvement of 29 letters on standard vision charts, and 78% gained at least 15 letters. The company reported no new safety signals through month 12, according to the funding announcement covered by Securities.io.
How will Science Corporation spend the $400 million?
The company plans to accelerate commercialization of Prima across Europe, prepare for a US launch through the FDA's Humanitarian Device Exemption pathway, and expand manufacturing and research infrastructure to support both. A portion is also earmarked for Science's newer biohybrid neural-interface program, which embeds stem-cell-derived neurons directly into electronics, an early-stage bet beyond vision restoration.
Who's backing Science, and how does it compare to Neuralink?
Science Corporation was founded in 2021 by Max Hodak, a Neuralink co-founder who left that company in 2021. Where Neuralink has focused on brain-computer interfaces for motor control and communication, Science has concentrated first on restoring sight through a photovoltaic implant before branching into biohybrid interfaces, positioning it as a neurotech competitor working a different entry point into implantable devices than its better-funded rival.
What's next for Prima?
The near-term milestone to watch is the FDA's response to a Humanitarian Device Exemption filing, which would open the US market to a device already selling in 30 European countries. Longer term, Science's biohybrid neuron-electronics work remains unproven outside early research, and investors will be watching whether that program produces data as concrete as Prima's 36-month trial results.